Alexion chief registers $16.5M in pay after a solid year, with a relatively low 74-to-1 ratio compared to a well paid staff
Image: Ludwig Alexion. ALEXION via TWITTER
Ludwig Hantson’s first full year running Alexion $ALXN in 2018 came with a bump in compensation as analysts provided some general applause for the biotech’s advances over the course of the year.
With their second-gen drug Ultomiris approved and on track to handle substantial patient conversions from Soliris, Hantson’s overall compensation package swelled to $16.5 million, about in line with the average that’s been paid to the Big Pharma execs who run substantially larger operations. It’s also generally well ahead of the European Big Pharma CEOs, who typically get to make do with less than their US peers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
